Retatrutide Beats Ozempic on Weight Loss and A1c in TRANSCEND-T2D-2, Lilly Reports
Lilly reports retatrutide roughly doubled Ozempic's weight loss and cut A1c further in TRANSCEND-T2D-2, but the triple-agonist peptide remains unapproved.
Read article →